1Kasahara Y, Yachie A.Cell type specific infection of Epstein-Barr virus(EBV) in EBV associated hemophago-cytic lymphohistiocytosis and chronic active EBV infection.Crit Rev Oncol Hematol, 2002, 44: 283-294.
2Kanegane H, Nomura K, Miyawaki T, et al.Biological aspects of Epstein-Barr virus(EBV) -infected lympho-cytes in chronic active EBV infection and associated malignancies.Crit Rev Oncol Hematol, 2002, 44: 239-249.
4Kasahara Y, Yachie A, Takei K, et al.Differential cellular targets of Epstein-Barr virus(EBV) infection between acute EBV associated hemophagocytic lymphohistiocytosis and chronic active EBV infection.Blood, 2001, 98: 1882-1888.
5Imashuku S, Hibi S, Todo S.Hemophagocytic lymphohistiocytosis in infancy and childhood.J Pediatr, 1997, 130: 352-357.
6Ishihara S, Okada S, Wakiguchi H, et al.Clonal lympho-proliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites.Am J Hematol, 1997, 54: 276-281.
7Imashuku S.Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.Crit Rev Oncol Hematol, 2002, 44: 259-272.
9Ohshima K, Suzumiya J, Sugihara M, et al.Clinicopatho-logical study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome.Pathol Int, 1998, 48: 934-943.
10Ueda I, Morimoto A, Inaba T, et al.Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan.Br J Haematol, 2003, 121: 503-510.
2Coffey A J, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet, 1998,20:129-135.
3Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH-2 domain encoding gene in X-linked lymphoproliferativesyndrome. Proc Nati Acad Sci USA, 1998,95:13765-13770.
4Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferativedisease gene product SAP regulates signals induced through the coreceptor SLAM. Nature, 1998, 395: 462-469.
5Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.Blood, 2000,96:3118-3125.
6Arico M, Imashuku S, Clementi R, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the Xlinked lymphoproliferative disease gene. Blood, 2001,97:1131-1133.
7Yin L, Ferrand V, Lavoue MF, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Gen, 1999,105:501-505.
8Lewis J, Eiben LJ, Nelson DL, et al. Distinct interactions of the Xlinked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol, 2001,100:15-23.
9Latour S, Gish G, Helgason CD, et al. Regulation of SLAMmediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol, 2001,2:681-690.
10Sayos J, Nguyen KB, Wu C, et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol, 2000,12:1749-1757.
